Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis
Publication
, Conference
Brander, D; Weinberg, JB; Friedman, D; Stewart, T; Rizzieri, D
Published in: LEUKEMIA & LYMPHOMA
December 1, 2017
Duke Scholars
Published In
LEUKEMIA & LYMPHOMA
EISSN
1029-2403
ISSN
1042-8194
Publication Date
December 1, 2017
Volume
58
Start / End Page
35 / 37
Publisher
TAYLOR & FRANCIS LTD
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Brander, D., Weinberg, J. B., Friedman, D., Stewart, T., & Rizzieri, D. (2017). Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis. In LEUKEMIA & LYMPHOMA (Vol. 58, pp. 35–37). TAYLOR & FRANCIS LTD.
Brander, Danielle, J Brice Weinberg, Daphne Friedman, Tiffany Stewart, and David Rizzieri. “Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis.” In LEUKEMIA & LYMPHOMA, 58:35–37. TAYLOR & FRANCIS LTD, 2017.
Brander D, Weinberg JB, Friedman D, Stewart T, Rizzieri D. Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis. In: LEUKEMIA & LYMPHOMA. TAYLOR & FRANCIS LTD; 2017. p. 35–7.
Brander, Danielle, et al. “Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis.” LEUKEMIA & LYMPHOMA, vol. 58, TAYLOR & FRANCIS LTD, 2017, pp. 35–37.
Brander D, Weinberg JB, Friedman D, Stewart T, Rizzieri D. Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis. LEUKEMIA & LYMPHOMA. TAYLOR & FRANCIS LTD; 2017. p. 35–37.
Published In
LEUKEMIA & LYMPHOMA
EISSN
1029-2403
ISSN
1042-8194
Publication Date
December 1, 2017
Volume
58
Start / End Page
35 / 37
Publisher
TAYLOR & FRANCIS LTD
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences